Advertisement

Behavioral Pharmacology of Anxiolytics

  • P. B. Dews
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 55 / 2)

Abstract

Anxiety is a term applied by clinicians to certain manifestations in patients. Clinical anxiety has three components. First there is a verbal component: The patient says that he or she is anxious or fearful or gives a semantically similar description. Second, there is a somatic-autonomic component. The patient is restless and agitated, has a higher heart rate, and sweats. Third, there is an interference with normal productive activities. Clinical anxiety should probably not be diagnosed if any of these three components is entirely lacking. In the clinical assessment of anxiety by history and physical examination, all three components are taken into account.

Keywords

Agonistic Behavior Minnesota Multiphasic Personality Inventory Clinical Anxiety Behavioral Pharmacology Anxiolytic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allen, J.A., Mewha, L.S., Roddie, I.C.: The effect of diazepam on performance and emotional response during viva examination. J. Physiol. (Lond.) 263, 191P–192P (1976)Google Scholar
  2. Barlow O.W.: The tranquilizing potency of morphine, pantopan, codeine, papaverine and narcotine. J. Am. Med. Ass. 99, 986–988 (1932)Google Scholar
  3. Berger, F.M., Bradley, W.: The pharmacological properties of α:β-dihydroxy-α-(2-methyl- phenoxy) propane (Myanesin). Br. J. Pharmacol. 1, 265–272 (1946)Google Scholar
  4. Brocklehurst, J.C., Carty, M.H., Skorecki, J.: The use of a kymograph in a comparative trial of flunitrazepam and meprobamate in elderly patients. Curr. Med. Res. Opin. 5, 663–668 (1978)PubMedCrossRefGoogle Scholar
  5. Burrows, G.D., Davies, B., Fail, L., Poynton, C., Stevenson, H.: A placebo controlled trial of diazepam and Oxprenolol for anxiety. Psychopharmacology 50, 177–179 (1976)PubMedCrossRefGoogle Scholar
  6. Derougatis, L.R., Lipman, R.S., Rickels, J., Uhlenhuth, E.H., Covi, L.: The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav. Sci. 19, 1–15 (1974)CrossRefGoogle Scholar
  7. Dews, P.B.: Effects of drugs on suppressed responding. Br. J. Pharmacol. 58, 451 P (1976)Google Scholar
  8. Dews, P.B., DeWeese, J.: Schedules of reinforcement. In Handbook of Psychopharmacology. Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds.), Vol. 7, pp. 107–150. New York: Plenum Press 1977Google Scholar
  9. Geller, I.H., Seifter, J.: The effects of meprobamate, barbituates, D-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia 1, 482–502 (1960)CrossRefGoogle Scholar
  10. Hamilton, M.: The assessment of anxiety states by rating. Br. J. Med. Psychol. 32, 50–55 (1959)PubMedCrossRefGoogle Scholar
  11. Henneman, E., Kaplan, A., Unna, K.: A neuropharmacological study on the effect of myanesin (Tolserol) on motor systems. J. Pharmacol. 97, 331–341 (1949)Google Scholar
  12. Hoff meister, F., Wuttke, W.: On the actions of psychotropic drugs on the attack — and aggressive — defensive behavior of mice and cats. In Aggressive behavior. Garattini, S., Sigg, E.B. (eds.), pp. 273–280. New York: Wiley 1969Google Scholar
  13. Kelleher, R.T., Fry, W., Deegan, J., Cook, L.: Effects of meprobamate on operant behavior in rats. J. Pharmacol. 133, 271–280 (1961)Google Scholar
  14. Linnoila, M., Mantilla, M.J.: Drug interaction or psychomotor skills related to driving: diazepam and alcohol. Eur. J. Clin. Pharmacol. 5, 186–194 (1973)CrossRefGoogle Scholar
  15. Miczek, K.A.: Intraspecies aggression in rats: effects of D-amphetamine and chlordiazepoxide. Psychopharmacologia 39, 275–301 (1974)PubMedCrossRefGoogle Scholar
  16. Miczek, K.A., Krsiak, M.: Drug effects on agonistic behavior. In Advances in behavioral pharmacology. Thompson, T., Dews, P.B. (eds.), Vol. 2, pp. 88–153. New York: Academic Press 1979Google Scholar
  17. Rickels, K., Pereira-Ogan, J., Csanalosi, I., Morris, R.J., Rosenfeld, H., Sablosky, L., Schless, A., Werbowsky, J.H.: Halazepam and diazepam in neurotic anxiety: A double blind study. Psychopharmacology 52, 129–136 (1977)PubMedCrossRefGoogle Scholar
  18. Rickels, K., Downing, R.W., Winokur, A.: Antianxiety drugs: Clinical use in psychiatry. In Handbook of Psychopharmacology. Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds.), Vol. 13, pp. 395–430. New York: Plenum 1978Google Scholar
  19. Sepinwall, J., Cook, L.: Behavioral pharmacology of antianxiety drugs. In Handbook of Psychopharmacology. Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds.), Vol. 13, pp. 345–385. New York: Plenum 1978Google Scholar
  20. Sternbach, L.H.: The benzodiazepine story. J. Med. Chem. 22, 1–7 (1979)PubMedCrossRefGoogle Scholar
  21. Taylor, J.A.: A personality scale of manifest anxiety. J. Abnorm. Soc. Psychol. 48, 285–290 (1953)CrossRefGoogle Scholar
  22. Weiss, B., Laties, V.: A critical review of the efficacy of meprobamate (Miltown, Equanil) in the treatment of anxiety. J. Chronic. Dis. 7, 500–519 (1958)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • P. B. Dews

There are no affiliations available

Personalised recommendations